ConductScience.org, home

Paper40677757

From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.

Zhang Z and 6 others. Bioact Mater, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies. Papers, record 40677757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40677757

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.
PubMed
Journal
Bioact Mater
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.29, provisional
iCite
Revised in PubMed
2025-07-20
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang ZZhan
2Wu YYuanzhen
3Liu YYanchen
4Zhang JJingyu
5Zhang YYan
6Dai YYunlu
7Liu CCaigang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References317

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132049413The Glutathione/Metallothionein System Challenges the Design of Efficient O2 -Activating Copper Complexes.Angew Chem Int Ed Engl2020https://conductscience.org/library/papers/32049413PubMed
237344759Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors.Drug Deliv2023https://conductscience.org/library/papers/37344759PubMed
333408792Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.Theranostics2021https://conductscience.org/library/papers/33408792PubMed
438708719Human Serum Albumin Mediated Controllable Synthesis of Defect-Rich Copper Hydroxide Nanowire for Cuproptosis-Based Anti-Tumor Therapy.Adv Healthc Mater2024https://conductscience.org/library/papers/38708719PubMed
538217522Cellular metabolism: A key player in cancer ferroptosis.Cancer Commun (Lond)2024https://conductscience.org/library/papers/38217522PubMed
635419582Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation.Biomater Sci2022https://conductscience.org/library/papers/35419582PubMed
737984863Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity.Adv Sci (Weinh)2024https://conductscience.org/library/papers/37984863PubMed
831165801Recent advances in nanomaterial-based synergistic combination cancer immunotherapy.Chem Soc Rev2019https://conductscience.org/library/papers/31165801PubMed
937442270Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?Metabolism2023https://conductscience.org/library/papers/37442270PubMed
1011303500Pro-inflammatory programmed cell death.Trends Microbiol2001https://conductscience.org/library/papers/11303500PubMed
1138799628Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy.Acta Pharm Sin B2024https://conductscience.org/library/papers/38799628PubMed
1229348297Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk.Ann Rheum Dis2018https://conductscience.org/library/papers/29348297PubMed
1337147285KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer.Nat Commun2023https://conductscience.org/library/papers/37147285PubMed
1437820717Self-Destructive Copper Carriers Induce Pyroptosis and Cuproptosis for Efficient Tumor Immunotherapy Against Dormant and Recurrent Tumors.Adv Mater2024https://conductscience.org/library/papers/37820717PubMed
1538364781GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis.Cell2024https://conductscience.org/library/papers/38364781PubMed
1639285820Multifunctional Copper-Phenolic Nanopills Achieve Comprehensive Polyamines Depletion to Provoke Enhanced Pyroptosis and Cuproptosis for Cancer Immunotherapy.Adv Mater2024https://conductscience.org/library/papers/39285820PubMed
1739567558Regulating copper homeostasis of tumor cells to promote cuproptosis for enhancing breast cancer immunotherapy.Nat Commun2024https://conductscience.org/library/papers/39567558PubMed
1819626597Copper in diseases and treatments, and copper-based anticancer strategies.Med Res Rev2010https://conductscience.org/library/papers/19626597PubMed
1935606443A pyroptosis nanotuner for cancer therapy.Nat Nanotechnol2022https://conductscience.org/library/papers/35606443PubMed
2037880907Photoinduced Cuproptosis with Tumor-Specific for Metastasis-Inhibited Cancer Therapy.Small2024https://conductscience.org/library/papers/37880907PubMed

See all 317 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42934669Trace elements and tumors: homeostatic networks, molecular mechanisms and new horizons for precision intervention.Mol Cancer2026https://conductscience.org/library/papers/42934669PubMed
42422020PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs.Innovation (Camb)2026https://conductscience.org/library/papers/42422020PubMed
41820292Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.Cell Death Discov2026https://conductscience.org/library/papers/41820292PubMed
41597186Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities.Cells2026https://conductscience.org/library/papers/41597186PubMed
41201667Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions.Mol Biomed2025https://conductscience.org/library/papers/41201667PubMed
41097635The FSIP Family: Roles in Health and Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/41097635PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40677757

GET https://conductscience.org/api/papers/v1/40677757/references?page=2